FDA issues stop business notice to Blinkit's dark store for operating sans FSSAI license
The notice was issued on June 5 to Energy Darkstore Services, one of Blinkit's last-mile warehousing and partners.
The dark store a month back had applied for an FSSAI license. The FDA Pune officials had put the license approval on hold due to incomplete documents. Even after one month, Energy Darkstore Services did not reach out to the food authority to complete the process. Following this, the FDA officials visited the warehouse and found the facility operating sans licence.
Suresh Annapure, joint commissioner, Pune region, said, 'A notice to stop business till the license is received has been issued to the dark store which was found operating sans necessary license as mandated by the Food Safety and Standards Act, 2006.'
'No food business operator can operate without an FSSAI license in the country. The dark store has been asked to complete the compliance and documentation on priority to get the license. After which a reinspection will be conducted by us, only after which the license will be issued,' added Annapure.
As per officials, during the visit, the facility was found distributing packaged food items and bulk storage racks. The store was operating with compromised sanitary and hygiene conditions with food debris and employees not covering their hair while storing and handling food items, they said. The unit had around 50 employees and had cold storage units for milk, milk products and fruits, they said.
On May 31 the FDA suspended the food business license of Kiranakart Technologies Pvt. Ltd.—the parent company of quick-commerce platform Zepto—for its Dharavi facility, citing serious violations of food safety and hygiene norms.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
13 hours ago
- Mint
Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug
(Bloomberg) -- Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to benefit patients after surgery and US regulators said they didn't see a path forward for broad use of its pill in treating a chronic pain condition. Vertex has been trying to diversify beyond its core business of cystic fibrosis treatments. A key part of that strategy has been its new non-opioid pain drug, Journavx, which got US regulatory clearance in January. It was the first new type of painkiller to reach the US market in more than two decades. Shares of Vertex Pharmaceuticals fell as much as 14% in premarket trading on Tuesday. The stock is up 17% since the start of the year through Monday's close. The company is also developing the pill, a safer alternative to addictive opioids, for chronic pain caused by nerve damage. US Food and Drug Administration staff members reviewing a study of the drug said they didn't see a path forward for widespread use in the condition at this time, Vertex said in a statement disclosing its second-quarter earnings results. The drugmaker also has been studying other drugs in its pipeline to see if they have better efficacy than Journavx. The experimental pain drug VX-993 failed in a mid-stage study for treating acute pain, and Vertex halted its development as a standalone therapy for the condition, it said in a separate statement. The setback at the FDA and mid-stage trial failure 'should cause a rethink of the overall opportunity and risk profile for the pain franchise,' RBC Capital Markets analyst Brian Abrahams said in a note. The drugmaker said it would conduct a second trial of Journavx in patients with diabetic peripheral neuropathy, and won't start a final study that was being planned in a different condition. Diabetic peripheral neuropathy is 20% of the neuropathic pain market, Abrahams said. More than 110,000 prescriptions for the medicine have been written and filled for acute pain conditions since it became available in early March, the company said. The novel pain drug VX-993 didn't yield a statistically significant benefit for patients getting bunionectomy surgery, the company said. The failure suggests 'it may be more challenging than some expected to iterate and improve upon' Journavx, Abrahams said in a note. The FDA's stance removes the potential for Vertex to capture the broadest chronic pain market, he said. The company also reported second-quarter revenue and profit that came in ahead of analyst estimates, and reaffirmed its full-year revenue view. Chief Scientific Officer David Altshuler announced his plan to retire on Aug. 1, 2026. Mark Bunnage, the current senior vice president of global research, will take over the role on Feb. 1 as part of a transition plan, the company announced. --With assistance from Subrat Patnaik. (Updates with premarket shares in the third paragraph.) More stories like this are available on
Deccan Herald
14 hours ago
- Deccan Herald
Shocked by how your cozy Mac n Cheese is made at your nearby restaurant? Instant complaints are now just a scan away!
The FSSAI has asked all eateries to display their FSSAI license/registration certificate with the QR code of Food Safety Connect app in areas visible to customers.
Economic Times
19 hours ago
- Economic Times
Swiggy vs Eternal: Which stock promises better value delivery post Q1 show?
Eternal and Swiggy, two of India's top food delivery and quick commerce (QC) players, have emerged from the June quarter with distinct narratives. While both companies posted strong growth, Eternal's margin visibility, Blinkit-led momentum, and balance sheet strength have tipped brokerage sentiment clearly in its favour. Swiggy, though making progress on unit economics, continues to battle margin pressure and cash burn, leaving analysts divided on its near-term prospects. ADVERTISEMENT Eternal, the parent of Zomato and Blinkit, reported a 55% year-on-year rise in B2C net order value (NOV) in Q1FY26. Blinkit, its quick commerce arm, delivered 140% YoY GOV growth, outpacing food delivery for the first time and marking QC as Eternal's largest segment. 'Q/C GOV is now ahead of foods, making Q/C the largest segment for Eternal,' noted Jefferies, adding that 'near-term margins have bottomed, and absolute losses should come down.' The brokerage, which had downgraded the stock in January over competition fears, reversed its stance, saying, 'We overestimated the competitive threat' and upgraded to a 'Buy' rating with a revised price target of Rs 400. Goldman Sachs similarly upgraded Blinkit's GOV estimates by up to 9%, calling out 'elevated growth with improving margin outlook.' The brokerage said it forecasts Blinkit's EBITDA breakeven by December 2025 and raised its 12-month target price on Eternal to Rs 340. 'We see that acting as a catalyst for the stock,' the brokerage said, citing improving quick commerce margin trends and a shift to an inventory ownership model. Emkay Global expects that as Blinkit transitions to a first-party inventory model in its quick commerce operations, it will be able to expand its margins by around 100 basis points, thanks to better control and efficiency, even as it scales up to as many as 3,000 stores. Food delivery remains the cash-generating engine, with management projecting 15–20% growth in FY26. ADVERTISEMENT Adjusted EBITDA margin in food delivery moderated slightly in Q1 to 4.2% of GOV, but Jefferies and Goldman Sachs both expect margin expansion over time, with the industry structure remaining favourable. Eternal ended Q1 with Rs 189 billion in cash, significantly higher than Swiggy's Rs 54 posted robust 45% YoY growth in B2C GOV, led by Instamart. However, rising costs and weak operating leverage weighed on margins. HSBC flagged the steep drop in profitability versus Eternal, noting: 'FD adj. EBITDA margin fell 50bp q-o-q in 1Q... quick commerce EBITDA loss still high at cINR9bn.' ADVERTISEMENT Swiggy delivered a strong 45% year-on-year rise in B2C gross order value (GOV) in the first quarter, driven primarily by Instamart. But gains on the top line were offset by escalating costs and muted operating leverage. HSBC flagged the widening profitability gap with rival Eternal, observing that 'FD adjusted EBITDA margin fell 50bp q-o-q in 1Q... quick commerce EBITDA loss still high at Rs 9 billion.'Swiggy's quick commerce arm, Instamart, saw strong AOV-led growth (16% q-o-q), aided by its MaxxSaver initiative. But HSBC said, 'Operating leverage is key now in the near term,' as orders per day per store remain about 40% lower than Blinkit. ADVERTISEMENT Cash burn for Q1 stood at Rs 13 billion, and while HSBC projects this to decline to Rs 8 billion by Q4, the brokerage cautioned, 'If capex and working capital investments do not fall sharply in coming quarters, we worry cash exhaustion could continue to be significant.' The brokerage retained a 'Hold' rating with a Rs 430 price Stanley raised its target to Rs 450, acknowledging Swiggy's improving unit economics but added, 'We still prefer Eternal over Swiggy.' The brokerage flagged risks around cash depletion and 'weaker store addition or space addition vs. Blinkit.' ADVERTISEMENT Jefferies took a contrarian view, upgrading Swiggy to a 'Buy' rating and lifting its price target to Rs 500. The brokerage described Swiggy as a 'high risk–high reward' play, saying, '1Q profitability marked the trough,' with management pausing store additions and focusing on profitability. The brokerage sees upside from the platform's growing non-grocery mix and stabilised 10-minute delivery via agree that Swiggy trades at lower valuations than Eternal, but that discount reflects execution risk. As HSBC put it, 'Valuations [are] lower than Eternal, but steep execution pick-up is needed.'Eternal, on the other hand, has delivered consistently in both food and quick commerce, with Blinkit's accelerated growth and shift to a first-party inventory model seen as value-accretive. Goldman Sachs forecast Blinkit reaching 5–6% EBITDA margins by FY30 and called the Q1 commentary 'positively surprising.'With cash burn narrowing and store productivity improving, Swiggy may yet turn sentiment, especially if it delivers on its margin targets and monetises its stake in Rapido. But for now, brokerages are overwhelmingly aligned: Eternal, with its superior execution, scale advantage, and margin visibility, is the better buy post-Q1. Also read | Paytm, Swiggy among 7 stocks that Jefferies upgraded after Q1 results (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
